Status:
COMPLETED
Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Lead Sponsor:
University of Miami
Collaborating Sponsors:
Aventis Pharmaceuticals
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study eval...
Detailed Description
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study eval...
Eligibility Criteria
Inclusion
- HER-2 overexpressing breast cancer
- Clinical stage 2-3B
- Normal ejection fraction
Exclusion
- Metastatic disease
- Low ejection fraction
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00232479
Start Date
September 1 2005
End Date
June 1 2008
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jackson Memorial Hospital
Miami, Florida, United States, 33136